Press releases
- Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
- Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
- Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
- Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
- Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
More ▼
Key statistics
On Friday, Sangamo Therapeutics Inc (SGMO:DEU) closed at 0.48, 100.84% above the 52 week low of 0.239 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.55 |
---|---|
High | 0.55 |
Low | 0.48 |
Bid | 0.462 |
Offer | 0.4761 |
Previous close | 0.481 |
Average volume | 8.06k |
---|---|
Shares outstanding | 207.51m |
Free float | 191.46m |
P/E (TTM) | -- |
Market cap | 103.78m USD |
EPS (TTM) | -1.86 USD |
Data delayed at least 15 minutes, as of Jun 14 2024.
More ▼